Savara (SVRA) is back in focus after new Phase 3 IMPALA-2 data showed its inhaled therapy molgramostim improved exercise capacity and reduced disease biomarkers in autoimmune pulmonary alveolar proteinosis patients.

Despite a modest pullback in the 1 day and 90 day share price returns, Savara’s stock has delivered a 1 year total shareholder return of 76.76% and a 5 year total shareholder return of 178.89%. These figures reflect how investors have reacted to recent Phase 3 data, launch preparation updates for MOLBREEVI and the latest quarterly loss.

If you are looking beyond a single rare disease stock, this could be a useful moment to see what else is shaping the future of medicine and technology through 34 healthcare AI stocks

After such strong multi year returns, but a pullback of around 10% year to date and a last close of US$5.02 against an analyst target of US$10.81, are you seeing a fresh opportunity here, or are markets already pricing in future growth?

Preferred Price-to-Book of 7.2x: Is it justified?

On a P/B basis, Savara currently trades at 7.2x, which sets a high bar for expectations compared to both its peers and the broader US Biotechs industry.

The P/B ratio compares the company’s market value to its book value, so a higher multiple often reflects strong confidence in future assets, profitability or both. For a clinical stage biopharmaceutical business with no meaningful revenue and ongoing losses, a high P/B usually signals that investors are heavily focused on potential future cash flows rather than current fundamentals.

Here, Savara’s P/B of 7.2x is described as expensive versus a peer average of 6.4x. This suggests the stock is priced at a premium even within its own comparison group. Against the wider US Biotechs industry average of 2.4x, the gap is even wider. This reinforces the idea that expectations for the pipeline and future revenue are materially higher than what the balance sheet alone might justify.

Result: Price-to-book of 7.2x (OVERVALUED)

However, investors still face key risks, including the company’s ongoing losses of US$129.482 million and its complete reliance on a single clinical stage asset.

Next Steps

Mixed signals so far, with both risks and rewards on the table, mean this is a good time to inspect the details yourself and move quickly. Start with 1 key reward and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that could fit your style, your risk tolerance and your time horizon.

• Spot potential bargains that balance quality with price by scanning 49 high quality undervalued stocks.
• Prioritize resilience and sleep easier at night by focusing on 66 resilient stocks with low risk scores.
• Hunt for lesser known opportunities with solid fundamentals using the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.